Quantcast

Latest Protease inhibitor Stories

2010-10-30 08:00:00

BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with ribavirin reduced viral load below the lower limit of quantifiable levels in HCV treatment-naive patients. The regimen did not include interferon through the first 28 days of...

2010-10-05 06:00:00

PITTSBURGH, Oct. 5 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Atazanavir Sulfate Capsules, 150 mg and 300 mg. This product will be eligible for purchase outside the U.S. in certain developing countries. Mylan President Heather...

2010-09-08 14:36:12

Switching from protease inhibitors to Nevirapine brings superior results for some HIV-Infected children Nevirapine is widely used to help prevent mother-to-child transmission of the HIV virus. In cases where the infants are nonetheless infected with HIV virus at birth, the standard treatment is to use protease inhibitors (PI) to reduce the amount of virus in their bloodstream. A new study involving 195 infants in South Africa found that children who were treated with PI and then switched to...

2010-09-07 15:00:00

BRISBANE, Calif., Sept. 7 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at three upcoming healthcare conferences. The conferences and presentation schedules are as follows: The 2010 Morgan Stanley Global Healthcare Conference in New York on September 13 at 2:10 p.m. EDT; The Robert W. Baird 2010 Health Care Conference in New York on September 14 at 2:45 p.m. EDT; and The...

2010-06-10 07:00:00

CAMBRIDGE, Mass., June 10 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype...

2010-05-21 06:00:00

BRISBANE, Calif., May 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steve Porter, M.D., Ph.D., Chief Medical Officer and Senior Vice President, Clinical Affairs of InterMune, will present at the 2010 Citi Health Care Conference in New York on May 26 at 3 p.m. EDT. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The...

2010-03-25 10:15:00

WALTHAM, Mass., March 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on available data and expert opinion, the telaprevir/peg-IFN-a-2a/ribavirin* regimen will earn Decision Resources proprietary clinical gold-standard status for the treatment of hepatitis C virus (treatment-naive population) in 2013, following telaprevir's approval for the indication in 2011. The...

2010-03-02 08:30:00

ABBOTT PARK, Ill. and WATERTOWN, Mass., March 2 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration into Phase 2 clinical trials. The trial will evaluate three HCV antiviral agents, including the investigational protease inhibitor ABT-450, part of the Abbott-Enanta collaboration, and polymerase inhibitors ABT-333 and ABT-072 currently being developed exclusively by Abbott. Each antiviral agent...

2010-01-06 15:05:00

BRISBANE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13 at 4:00 p.m. PST. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company...

2009-12-11 15:00:00

BRISBANE, Calif., Dec. 11 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Steve Porter, M.D., Chief Medical Officer of InterMune, will present at the 2009 DB-Biotech Boston Confab on December 15, 2009 at 9:30 a.m. EST. To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related